Citation Impact
Citing Papers
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
2020
The biology and management of non-small cell lung cancer
2018 StandoutNature
Macrophages in immunoregulation and therapeutics
2023 Standout
Understanding and targeting resistance mechanisms in NSCLC
2017
Targeting apoptosis in cancer therapy
2020 Standout
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
2017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Works of Anna Wrona being referenced
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
2016
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
2018